L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study

Published:2017-05-08 Issue:4 Volume:32 Page:e2584
ISSN:0885-6222
Container-title:Human Psychopharmacology: Clinical and Experimental
language:en
Short-container-title:Hum. Psychopharmacol Clin Exp

Author:

Arabzadeh Somaye¹,Shahhossenie Maryam¹,Mesgarpour Bita²,Rezaei Farzin³,Shalbafan Mohammad Reza⁴,Ghiasi Zahra⁵,Akhondzadeh Shahin¹^ORCID

Affiliation:

1. Psychiatric Research Center, Roozbeh Hospital; Tehran University of Medical Sciences; Tehran Iran

2. National Institute for Medical Research Development (NIMAD); Tehran Iran

3. Qods Hospital; Kurdistan University of Medical Sciences; Sanandaj Iran

4. Mental Health Research Center, School of Medicine; Iran University of Medical Sciences; Tehran Iran

5. Department of Psychiatry; Zahedan University of Medical Sciences; Zahedan Iran

Funder

Tehran University of Medical Sciences and Health Services

Publisher

Wiley

Subject

Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical),Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hup.2584/fullpdf

Reference46 articles.

1. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial;Aboujaoude;Journal of Clinical Psychopharmacology,2009

2. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study;Akhondzadeh;Progress in Neuro-Psychopharmacology & Biological Psychiatry,2008

3. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial;Askari;CNS Drugs,2012

4. An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder;Bakhla;Industrial Psychiatry Journal,2013

5. Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder;Bhattacharyya;Neuropsychopharmacology,2009

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists in augmentation with selective serotonin reuptake inhibitors (SSRIs) in the treatment of moderate to severe obsessive–compulsive disorder: a systematic review and meta-analysis of randomized clinical trials;Scientific Reports;2023-11-27

2. Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial;BMC Psychiatry;2023-09-21

3. L‐theanine combination therapy with fluvoxamine in moderate‐to‐severe obsessive–compulsive disorder: A placebo‐controlled, double‐blind, randomized trial;Psychiatry and Clinical Neurosciences;2023-05-27

4. Efficacy of 5-hydroxytryptamine-3 (5-HT3) antagonists adjuvant therapy for moderate to severe obsessive–compulsive disorder: A systematic review and meta-analysis of randomized clinical trials;2023-04-24

5. Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial;2023-03-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3